HKG Epitherapeutics ("HKG" or "the Company), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, has received renewed accreditation from the College of American Pathologists (CAP). The renewal was awarded to HKG based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
For the full article click here: HKG EPITHERAPEUTICS RECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS